Gossamer Bio Executes 1-for-80 Reverse Split to Regain Nasdaq Compliance

summarizeSummary

Gossamer Bio finalized a 1-for-80 reverse stock split to regain Nasdaq minimum bid compliance, effective September 10, 2026, with trading on a split-adjusted basis starting September 11.

check_boxKey Events · Corporate Governance and Compliance · GOSS

• 1-for-80 Reverse Split Selected

  Board chose a 1-for-80 reverse stock split ratio, effective September 10, 2026 at 11:59 p.m. ET, with split-adjusted trading on Nasdaq beginning September 11 under new CUSIP 38341P 201.

• Nasdaq Compliance Objective

  The reverse split is intended to help the company regain compliance with Nasdaq's minimum bid price requirement, addressing delisting risk previously disclosed in the Q2 10-Q.

• Authorized Share Reduction

  Authorized common shares reduced from 4,000,000,000 to 50,000,000; total authorized capital stock reduced from 4,070,000,000 to 120,000,000.

• Proportional Adjustments to Derivatives

  Conversion rates on convertible notes, warrant and prefunded warrant exercise prices, and equity award share counts will be proportionately adjusted for the 1-for-80 ratio.

auto_awesomeAnalysis · GOSS · Life Sciences

Gossamer Bio's board selected a 1-for-80 reverse stock split, effective September 10, 2026, with trading on a split-adjusted basis beginning September 11. The move is designed to lift the stock price above Nasdaq's $1.00 minimum bid requirement — a critical step given the company's going-concern warning and delisting risk disclosed in its Q2 10-Q. The split also reduces authorized common shares from 4 billion to 50 million, proportionally adjusting convertible notes, warrants, and equity awards. While the split itself does not change ownership percentages, it is a survival mechanism for a company with cash runway only into Q1 2027.